AstraZeneca: Alexion Advances Commitment To Transform Patient Outcomes In Rare Neurological Diseases At AAN 2023
March 03, 2023
March 03, 2023
WILMINGTON, Delaware, March 3 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
Alexion, AstraZeneca Rare Disease, will showcase the potential for its pioneering therapies to redefine the treatment landscape for certain rare neurological diseases at the American Academy of Neurology (AAN) Annual Meeting, April 22-27, 2023. The company will present 19 abstracts, including eight oral presentations, across generalized myasthenia gravis (gMG), neuromyelitis . . .
Alexion, AstraZeneca Rare Disease, will showcase the potential for its pioneering therapies to redefine the treatment landscape for certain rare neurological diseases at the American Academy of Neurology (AAN) Annual Meeting, April 22-27, 2023. The company will present 19 abstracts, including eight oral presentations, across generalized myasthenia gravis (gMG), neuromyelitis . . .